Season 1

Congress and the new Biden White House are ready to hit the ground running in 2021. So we’re here to make sure patient needs are addressed and included in upcoming legislation. On this episode, Terry outlines the Pro-Patient ...

The Most Favored Nation Rule will take effect on January 1st. It’s bad news for Medicare infusion patients and providers, but there’s still time to stop it. The rule makes it financially impossible for medical practices to of...

Navigating the legal issues that come with a cancer diagnosis is challenging. From employer discrimination to financial toxicity, legal consultation provides much-needed peace of mind and guidance. Shelly Rosenfeld makes her ...

As President-elect Joe Biden makes his health team picks, we discuss what patients may expect out of a new Democratic Administration and increased Republican seats in the U.S. House. We bring policy experts from both sides o...

Can Republicans and Democrats work together to help the chronic disease community? Former FDA Commissioner Dr. Mark McClellan predicts what healthcare challenges may benefit from bipartisan support in the new year. Plus, he o...

In the wake of Alex Trebek’s passing, we take a look at the state of pancreatic cancer treatments and care. Julie Fleshman, CEO of the Pancreatic Cancer Action Network, gives insights into the increase in treatment options. P...

Precision medicine is revolutionizing cancer care. Dr. Razelle Kurzrock highlights how personalized treatments improve patient outcomes and quality of life. Plus, it’s enrollment season! Get the information you need for Medic...

Power to patients! A new price transparency rule from the U.S. Department of Health and Human Services will allow you to see exactly what you’re paying for. Terry and Dr. Bob discuss the rule that will require private insurer...

As a heated election season wraps up, Terry and Dr. Bob examine the latest results and what they mean for patients and federal healthcare policy. Dr. Madelaine Feldman discusses tactics used by pharmacy benefit managers (PBMs...

Gene therapies can be lifesaving for many patients. But accessing them can be a challenge of its own. Terry and Dr. Bob discuss the private sector’s work to improve accessibility with Biotech executive John Crowley, who share...

States have begun to release their vaccine distribution plans, and President Trump and Biden spent the final debate sparring over the vaccine delivery timeline. The media says conflicting things. What should you believe, and ...

Drug pricing continues to make the news, so we’re revisiting our conversation with Dr. Janet Woodcock of the FDA about bringing drug manufacturing back to the U.S. Hear how American-made drugs might lower costs and improve ov...

President Trump’s apparent quick and successful battle with the COVID-19 virus should set the standard for care that all Americans should receive. Terry and Dr. Bob look at how the White House is grappling with spreading infe...

The future of the Affordable Care Act is uncertain with a Supreme Court vacancy. Terry and Dr. Bob discuss protections for preexisting conditions, and Congressman Michael Burgess speaks on the need for price transparency and ...

Cancer research may yield a potential COVID-19 therapeutic. Dr. Bob interviews Dr. John Rothman of Tyme Technologies about the promising preclinical studies for a new therapeutic. Plus, Kate speaks with Michelle Whitlock, a t...

The finish line for the vaccine race is just around the corner. Terry and Dr. Bob react to vaccine developments and respond to ICER’s recent attacks. Plus, the second part of our interview with Dr. Robert Popovian gives us th...

Get an inside look into the drug supply chain and the factors that impact your bill at the pharmacy counter. Dr. Robert Popovian, VP of Government Relations at Pfizer, joins Terry to discuss how benefit design and rebates imp...

In celebration of Labor Day, we look at a business that is empowering the chronic disease community. Kate interviews Keisha Greaves, founder of the clothing brand Girls Chronically Rock. Plus, Terry and Dr. Bob discuss a pote...

The lives of chronic and rare disease patients depend on the progress of medical discoveries. Dr. Gary Michelson explains how investment in innovative, high-risk research will improve patient outcomes. Plus hear from Lindsey ...

ICER’s pricing models assess the value of a drug and whether your life is worth paying for it. Health economist Dr. Paul Langley explains how ICER’s recommendations devalue patient lives and create barriers to accessible trea...

With a vaccine still months away, Americans with chronic disease are adapting to life with COVID-19. Dr. Paul Offit returns to discuss the status of a vaccine and living with the risk of infection. Terry and Bob consider scho...

Patients deserve easy access to their medical records. With digital healthcare solutions on the rise, new companies are providing patient-centric solutions to gather, own, and share personal health data. Dr. Bob speaks with S...

President Trump’s recent executive orders are a move to lower prescription drug prices for patients. But what changes should patients expect to see? We talk to the former lead health advisor to President Trump, Katy Talento, ...

Value-based healthcare models are a way to improve patient outcomes and lower the cost of care. Dr. Bob speaks with former FDA and CMS chief Dr. Mark McClellan, who says the pandemic has shown the benefits of value-based care...